JNJ Oncology Growth Replaces STELARA Defense In Strategy

Johnson & Johnson executives have shifted their corporate focus from defending the STELARA franchise to building a leading position in cancer medicines. The company now projects oncology sales to exceed $50 billion by 2030, a target that management outlined during the fiscal Q3 2026 earnings call.

This strategic pivot marks a distinct change from the prior year. During the fiscal Q3 2025 call, leadership emphasized the company's ability to maintain growth despite the loss of exclusivity for STELARA, the point at which competitors can sell biosimilar copies of the drug. One year later, the defensive posture regarding that specific drug has been superseded by an ambition to become the number one oncology company by 2030.

The financial data supports the transition in priority. In fiscal Q3 2026, the oncology business grew by approximately 17%, while STELARA sales continued to decline. Management attributed the drop in STELARA revenue to competition from biosimilars and a broader shift toward newer treatment classes. Despite this drag, overall company revenue for the twelve months ending in June 2026 reached $97.9 billion, an 8.1% increase from the previous year. This growth rate accelerated from the 4.7% increase recorded in the preceding twelve-month period.

Investors are currently paying a premium for this trajectory. Johnson & Johnson stock trades at 29.2 times earnings, compared to 22.9 for the S&P 500. The company’s ability to sustain growth while STELARA shrinks is central to justifying that valuation. During the fiscal Q2 2026 call in July, executives noted that sales grew at double-digit rates when excluding STELARA, even as total sales rose 5.6% with a drag of about 460 basis points from the drug.

The scale of the new oncology target is significant relative to the firm's entire operation. The projected $50 billion in cancer sales by 2030 would represent more than half of the $94.2 billion Johnson & Johnson sold across its entire business in fiscal 2025.

Management also raised the midpoint of its fiscal 2026 forecast for operational sales growth, narrowing the target range to 6.7% to 7.1%. However, the 2030 cancer target remains a forecast rather than an achieved result. A single quarter of fast growth does not yet establish a long-term trend, meaning shareholders paying today's premium are effectively underwriting future oncology performance.

The next key milestone for assessing this shift is scheduled for on or around January 26, 2027, when Johnson & Johnson is expected to release its next set of results. Growth in the oncology business will be the primary metric to watch at that time.